Blank C - Search Results

1

Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy).

Ascierto PA, Puzanov I, Agarwala SS, Blank C, Carvajal RD, Demaria S, Dummer R, Ernstoff M, Ferrone S, Fox BA, Gajewski TF, Garbe C, Hwu P, Lo RS, Long GV, Luke JJ, Osman I, Postow MA, Sullivan RJ, Taube JM, Trinchieri G, Zarour HM, Caracò C, Thurin M. Ascierto PA, et al. Among authors: blank c. J Transl Med. 2020 Sep 7;18(1):346. doi: 10.1186/s12967-020-02482-x. J Transl Med. 2020. PMID: 32894202 Free PMC article.

2

Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells.

Hwang KW, Sweatt WB, Brown IE, Blank C, Gajewski TF, Bluestone JA, Alegre ML. Hwang KW, et al. Among authors: blank c. J Immunol. 2002 Jul 15;169(2):633-7. doi: 10.4049/jimmunol.169.2.633. J Immunol. 2002. PMID: 12097362

3

Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells.

Blank C, Brown I, Marks R, Nishimura H, Honjo T, Gajewski TF. Blank C, et al. J Immunol. 2003 Nov 1;171(9):4574-81. doi: 10.4049/jimmunol.171.9.4574. J Immunol. 2003. PMID: 14568931

4

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.

Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF. Blank C, et al. Cancer Res. 2004 Feb 1;64(3):1140-5. doi: 10.1158/0008-5472.can-03-3259. Cancer Res. 2004. PMID: 14871849

5

Negative regulation of T-cell function by PD-1.

Zha Yy, Blank C, Gajewski TF. Zha Yy, et al. Among authors: blank c. Crit Rev Immunol. 2004;24(4):229-37. doi: 10.1615/critrevimmunol.v24.i4.10. Crit Rev Immunol. 2004. PMID: 15588223 Review.

6

Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.

Blank C, Gajewski TF, Mackensen A. Blank C, et al. Cancer Immunol Immunother. 2005 Apr;54(4):307-14. doi: 10.1007/s00262-004-0593-x. Epub 2004 Dec 15. Cancer Immunol Immunother. 2005. PMID: 15599732 Free PMC article. Review.

7

ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo.

Blank C, Brown I, Kacha AK, Markiewicz MA, Gajewski TF. Blank C, et al. J Immunol. 2005 Mar 15;174(6):3416-20. doi: 10.4049/jimmunol.174.6.3416. J Immunol. 2005. PMID: 15749875

8

Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.

Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, Majdic O, Gajewski TF, Theobald M, Andreesen R, Mackensen A. Blank C, et al. Int J Cancer. 2006 Jul 15;119(2):317-27. doi: 10.1002/ijc.21775. Int J Cancer. 2006. PMID: 16482562 Free article.

9

Immune resistance orchestrated by the tumor microenvironment.

Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, Harlin H. Gajewski TF, et al. Among authors: blank c. Immunol Rev. 2006 Oct;213:131-45. doi: 10.1111/j.1600-065X.2006.00442.x. Immunol Rev. 2006. PMID: 16972901 Review.

10

Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection.

Brown IE, Blank C, Kline J, Kacha AK, Gajewski TF. Brown IE, et al. Among authors: blank c. J Immunol. 2006 Oct 1;177(7):4521-9. doi: 10.4049/jimmunol.177.7.4521. J Immunol. 2006. PMID: 16982889

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

548 results

Search Page